HPSE and colitis: We will also study the effect of our lead compounds on other pathological indications involving heparanase, such as chronic inflammation (i.e., colitis, pancreatitis) [51,52], tissue fibrosis [53], kidney dysfunction (i.e., AKI, diabetic nephropathy) [54,55,56,57], and diabetes [58].